Publikation

Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).

Wissenschaftlicher Artikel/Review - 23.07.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Br J Clin Pharmacol 2022; 88
Veröffentlichungsdatum
23.07.2022
eISSN (Online)
1365-2125
Seiten
5336-5347
Kurzbeschreibung/Zielsetzung

Locally advanced rectal cancer (LARC) is an area of unmet medical need with one third of patients dying from their disease. With response to neoadjuvant chemo-radiotherapy being a major prognostic factor, trial SAKK 41/16 assessed potential benefits of adding regorafenib to capecitabine-amplified neoadjuvant radiotherapy in LARC patients.